# Molecular Insights into the Synergistic Anticancer and Oxidative Stress–Modulating Activity of Quercetin and Gemcitabine

**Authors:** Yasemin Afşin, Senem Alkan Akalın, İlhan Özdemir, Mehmet Cudi Tuncer, Şamil Öztürk

PMC · DOI: 10.3390/antiox15010091 · Antioxidants · 2026-01-10

## TL;DR

Quercetin enhances the effectiveness of gemcitabine in breast cancer by modulating oxidative stress and promoting cell death.

## Contribution

The study reveals a synergistic redox-based mechanism of quercetin and gemcitabine in inducing apoptosis in chemoresistant breast cancer cells.

## Key findings

- Combination treatment of quercetin and gemcitabine significantly reduced cell viability and enhanced apoptosis in MDA-MB-231 cells.
- Quercetin and gemcitabine induced oxidative stress by depleting GSH and increasing MDA, leading to pro-apoptotic effects.
- The combination downregulated HIF-1α and VEGF while upregulating Bax and Caspase-3, indicating suppression of hypoxia-driven survival.

## Abstract

Quercetin (Q), a bioactive flavonoid, exerts potent antioxidant and redox-modulating effects by activating the nuclear factor erythroid 2-related factor 2/antioxidant response Element (Nrf2/ARE) pathway and upregulating endogenous antioxidant defenses, including enzymatic antioxidants such as superoxide dismutase (SOD) and catalase (CAT), as well as non-enzymatic glutathione (GSH) and lipid peroxidation (MDA). Gemcitabine (Gem), a widely used antimetabolite chemotherapeutic, often shows limited efficacy under hypoxic and oxidative stress conditions driven by hypoxia-inducible factor 1-alpha (HIF-1α) and vascular endothelial growth factor (VEGF)-mediated angiogenesis. This study investigated the redox-mediated synergistic effects of Q and Gem in MDA-MB-231 human breast cancer cells. Combination treatment significantly reduced cell viability beyond the expected Bliss value, indicating a synergistic interaction and enhanced apoptosis compared with single-agent treatments. Increased reactive oxygen species (ROS) production was accompanied by depletion of GSH and accumulation of MDA, establishing a pro-apoptotic oxidative stress environment. Q alone enhanced SOD and CAT activities, whereas the combination induced exhaustion of antioxidant defenses under oxidative load, reflecting a redox-adaptive response. Molecular analyses revealed downregulation of HIF-1α and VEGF, alongside upregulation of Bax and Caspase-3, confirming suppression of hypoxia-driven survival and activation of the intrinsic apoptotic pathway. Transcriptomic and enrichment analyses further identified modulation of oxidative stress- and apoptosis-related pathways, including phosphoinositide-3-kinase–protein kinase B/Akt (PI3K/Akt), HIF-1 and VEGF signaling. Collectively, these results indicate that Q potentiates Gem cytotoxicity via redox modulation, promoting controlled ROS elevation and apoptosis while suppressing hypoxia-induced survival mechanisms, highlighting the therapeutic potential of redox-based combination strategies against chemoresistant breast cancer.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], are (Arylesterase) [NCBI Gene 59246804], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], Casp3 (caspase 3) [NCBI Gene 12367]
- **Chemicals:** Quercetin (PubChem CID 5280343), Gemcitabine (PubChem CID 60750), GSH (PubChem CID 124886), MDA (PubChem CID 1614)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CAT (catalase) [NCBI Gene 847], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** breast cancer (MESH:D001943), hypoxia (MESH:D000860), hypoxic (MESH:D002534), cytotoxicity (MESH:D064420)
- **Chemicals:** flavonoid (MESH:D005419), MDA (MESH:D015104), Gem (MESH:D000093542), Quercetin (MESH:D011794), ROS (MESH:D017382), Q (MESH:D005973), lipid (MESH:D008055), GSH (MESH:D005978)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12837379/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12837379/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12837379/full.md

---
Source: https://tomesphere.com/paper/PMC12837379